Difficulty: Medium
Average Score: 93%
Practice
Why would a child diagnosed with beta thalassemia and hemosiderosis receive deferoxamine (Desferal)?
Correct answer
D
Rationale
In the case of a child diagnosed with beta thalassemia and hemosiderosis, the correct answer is D) To eliminate excessive iron and prevent organ damage. Deferoxamine (Desferal) is a chelating agent used to remove excess iron from the body. Patients with beta thalassemia often require frequent blood transfusions, which can lead to iron overload and hemosiderosis, a condition characterized by the accumulation of iron in tissues and organs. Excessive iron can cause organ damage, particularly to the heart and liver, so the administration of deferoxamine helps to prevent these complications by binding to the excess iron and facilitating its excretion from the body.
Option A) To prevent blood transfusion reactions is incorrect because deferoxamine is not used to prevent reactions to blood transfusions, but rather to address iron overload.
Option B) To stimulate red blood cell production is incorrect because deferoxamine does not directly stimulate red blood cell production. It is primarily used to chelate excess iron.
Option C) To improve the oxygen-carrying capacity of RBCs is incorrect because while iron is essential for oxygen transport in red blood cells, the primary purpose of administering deferoxamine in this context is to address iron overload, not to enhance oxygen-carrying capacity.
In an educational context, understanding the rationale behind the use of deferoxamine in patients with beta thalassemia and hemosiderosis highlights the importance of managing iron overload in these individuals to prevent serious complications. It also underscores the significance of pharmacological interventions in addressing specific pathophysiological processes in patients with complex medical conditions.
Option A) To prevent blood transfusion reactions is incorrect because deferoxamine is not used to prevent reactions to blood transfusions, but rather to address iron overload.
Option B) To stimulate red blood cell production is incorrect because deferoxamine does not directly stimulate red blood cell production. It is primarily used to chelate excess iron.
Option C) To improve the oxygen-carrying capacity of RBCs is incorrect because while iron is essential for oxygen transport in red blood cells, the primary purpose of administering deferoxamine in this context is to address iron overload, not to enhance oxygen-carrying capacity.
In an educational context, understanding the rationale behind the use of deferoxamine in patients with beta thalassemia and hemosiderosis highlights the importance of managing iron overload in these individuals to prevent serious complications. It also underscores the significance of pharmacological interventions in addressing specific pathophysiological processes in patients with complex medical conditions.